Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
ApexOnco Front Page
Recent articles
After setbacks, cema-cel might have a path to approval in lymphoma.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
RMC-5127 becomes the company’s fourth clinical project.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
